Nonalcoholic Liver Disease: Mechanisms, Prevention, and Treatment
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 63
Special Issue Editors
Interests: liver disease; NAFLD; NASH; chronic hepatitis C; chronic hepatitis B; hepatocellular carcinoma; liver fibrosis; gene profiling; SNPs; transcriptomic analysis; GWAS
Special Issues, Collections and Topics in MDPI journals
Interests: study of molecular mechanisms involved in MAFLD development and progression in terms of MASH and HCC; evaluation of the effects of compounds and phytonutrient administration, potentially capable of improving the lipid and glucose metabolic profiles, as well as steatosis and hepatic fibrosis, on in vitro models of continuous human hepatoma cell lines (HepG2) and hepatic stellate cells (LX2)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The globally estimated prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) is 25.2% and includes a wide spectrum of clinical features from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), characterized by necroinflammation and liver fibrosis, which is associated with high-risk complications, such as liver decompensation and hepatocellular carcinoma. MAFLD is characterized by clinical phenotipic heterogeneity due to its multifactorial etiology, which includes the presence of comorbidities (i.e. obesity, insulin resistance, type 2 diabetes mellitus), diet and behavior, but a key role in FLD inter-individual variation is played by the subject's genetic and epigenetic background. Lifestyle changes based on caloric restriction, the Mediterranean diet and physical activities are recommended for MAFLD prevention. However, currently, there are no approved therapeutics available for MAFLD, although several classes of drugs for MAFLD/MASH treatment are under development (i.e., FXR agonists, PPAR agonists). Genomic studies are revolutionizing the comprehension of MAFLD, improving patient stratifcation for clinical trials and for prognostication in the era of personalized medicine.
Dr. Stefania Grimaudo
Dr. Rosaria Maria Pipitone
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MAFLD
- MASH
- metabolic syndrome
- steatosis
- lipid droplets
- SNPs
- GWAS
- therapeutc target
- fatty liver
- steatohepatitis
- HCC
- EpigEnetics
